The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
Tofacitinib (TOFA), a representative of a new class of targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is a promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases.Objective: to evaluate the efficiency and safety of therapy with TOFA in combin...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/732 |
id |
doaj-839287e5b05248d6961f1e62357d6a26 |
---|---|
record_format |
Article |
spelling |
doaj-839287e5b05248d6961f1e62357d6a262021-07-29T09:00:11ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2017-03-01111121810.14412/1996-7012-2017-1-12-182014The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational studyD. E. Karateev0D. E. Abdulganieva1A. R. Babaeva2A. A. Baranov3L. P. Evstigneeva4O. N. Ivanova5G. V. Lukina6E. L. Luchikhina7V. I. Mazurov8A. S. Misiyuk9O. V. Semagina10A. E. Sizikov11V. N. Sorotskaya12V.A. Nasonova Research Institute of RheumatologyRepublican Clinical Hospital, Ministry of Health of the Republic of TatarstanCity Clinical Hospital FourYaroslavl State Medical University, Ministry of Health of RussiaSverdlovsk Regional Clinical Hospital OneVoronezh Regional Clinical Hospital OneV.A. Nasonova Research Institute of Rheumatology Moscow Clinical Research and Practical Center, Moscow Healthcare DepartmentV.A. Nasonova Research Institute of RheumatologyI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyM.I. Kalinin Samara Regional HospitalResearch Institute of Fundamental and Clinical Immunology, Siberian Branch, Russian Academy of SciencesTula Regional Clinical HospitalTofacitinib (TOFA), a representative of a new class of targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is a promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases.Objective: to evaluate the efficiency and safety of therapy with TOFA in combination with methotrexate (MTX) and other s-DMARDs in real clinical practice in patients with active RA and previous ineffective therapy.Patients and methods. A 6-month Russian multicenter study of function and quality of life enrolled 101 patients with resistant RA: 18 men and 83 women; mean age, 51.03±11.28 years; mean disease duration, 105.4±81.43 months; rheumatoid factor-positive individuals (89.1%); and anticyclic citrullinated peptide antibody-positive ones (74.7%). 93 (92,1%) of these patients completed a 24-week study. TOFA was used as both second-line drug (after failure of therapy with s-DMARD) (n=74) and as a third-line drug (after failure of therapy with s-DMARDs and biological agents (BAs) (n=74). The tools RAPID3, HAQ, and EQ-5D were used to determine disease outcomes from a patient's assessment.Results. All the three tools demonstrated significant positive changes at 3–6 months following therapy initiation. RAPID3 scores for the status of a patient achieving a low disease activity or remission coincided with the mean DAS28-ESR and SDAI scores in 60% and 68% of cases, respectively. The achievement rates of the minimally clinically significant improvement (ΔHAQ≥0.22) and functional remission (HAQ≤0.5) at 6 months of TOFA therapy were 79.6 and 30.1%, respectively. The mean change value in EQ-5D scores over 6 months was -0.162±0.21. There were no significant between the groups of patients who used TOFA as a second- or third-line agent in the majority of indicators, except EQ-5D scores at 6 months.Conclusions. The results of our multicenter study using considerable Russian material confirmed the pronounced positive effect of TOFA used as a second-line agent (after s-DMARD failure) and a third-line agent (after s-DMARD and BA failure) on patients' assessment of disease activity, functional ability in daily life, and quality of life.https://mrj.ima-press.net/mrj/article/view/732rheumatoid arthritisfunctional abilityquality of lifetofacitinib. |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
D. E. Karateev D. E. Abdulganieva A. R. Babaeva A. A. Baranov L. P. Evstigneeva O. N. Ivanova G. V. Lukina E. L. Luchikhina V. I. Mazurov A. S. Misiyuk O. V. Semagina A. E. Sizikov V. N. Sorotskaya |
spellingShingle |
D. E. Karateev D. E. Abdulganieva A. R. Babaeva A. A. Baranov L. P. Evstigneeva O. N. Ivanova G. V. Lukina E. L. Luchikhina V. I. Mazurov A. S. Misiyuk O. V. Semagina A. E. Sizikov V. N. Sorotskaya The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study Современная ревматология rheumatoid arthritis functional ability quality of life tofacitinib. |
author_facet |
D. E. Karateev D. E. Abdulganieva A. R. Babaeva A. A. Baranov L. P. Evstigneeva O. N. Ivanova G. V. Lukina E. L. Luchikhina V. I. Mazurov A. S. Misiyuk O. V. Semagina A. E. Sizikov V. N. Sorotskaya |
author_sort |
D. E. Karateev |
title |
The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study |
title_short |
The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study |
title_full |
The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study |
title_fullStr |
The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study |
title_full_unstemmed |
The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study |
title_sort |
effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: results of a multicenter observational study |
publisher |
IMA-PRESS LLC |
series |
Современная ревматология |
issn |
1996-7012 2310-158X |
publishDate |
2017-03-01 |
description |
Tofacitinib (TOFA), a representative of a new class of targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is a promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases.Objective: to evaluate the efficiency and safety of therapy with TOFA in combination with methotrexate (MTX) and other s-DMARDs in real clinical practice in patients with active RA and previous ineffective therapy.Patients and methods. A 6-month Russian multicenter study of function and quality of life enrolled 101 patients with resistant RA: 18 men and 83 women; mean age, 51.03±11.28 years; mean disease duration, 105.4±81.43 months; rheumatoid factor-positive individuals (89.1%); and anticyclic citrullinated peptide antibody-positive ones (74.7%). 93 (92,1%) of these patients completed a 24-week study. TOFA was used as both second-line drug (after failure of therapy with s-DMARD) (n=74) and as a third-line drug (after failure of therapy with s-DMARDs and biological agents (BAs) (n=74). The tools RAPID3, HAQ, and EQ-5D were used to determine disease outcomes from a patient's assessment.Results. All the three tools demonstrated significant positive changes at 3–6 months following therapy initiation. RAPID3 scores for the status of a patient achieving a low disease activity or remission coincided with the mean DAS28-ESR and SDAI scores in 60% and 68% of cases, respectively. The achievement rates of the minimally clinically significant improvement (ΔHAQ≥0.22) and functional remission (HAQ≤0.5) at 6 months of TOFA therapy were 79.6 and 30.1%, respectively. The mean change value in EQ-5D scores over 6 months was -0.162±0.21. There were no significant between the groups of patients who used TOFA as a second- or third-line agent in the majority of indicators, except EQ-5D scores at 6 months.Conclusions. The results of our multicenter study using considerable Russian material confirmed the pronounced positive effect of TOFA used as a second-line agent (after s-DMARD failure) and a third-line agent (after s-DMARD and BA failure) on patients' assessment of disease activity, functional ability in daily life, and quality of life. |
topic |
rheumatoid arthritis functional ability quality of life tofacitinib. |
url |
https://mrj.ima-press.net/mrj/article/view/732 |
work_keys_str_mv |
AT dekarateev theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT deabdulganieva theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT arbabaeva theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT aabaranov theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT lpevstigneeva theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT onivanova theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT gvlukina theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT elluchikhina theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT vimazurov theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT asmisiyuk theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT ovsemagina theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT aesizikov theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT vnsorotskaya theeffectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT dekarateev effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT deabdulganieva effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT arbabaeva effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT aabaranov effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT lpevstigneeva effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT onivanova effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT gvlukina effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT elluchikhina effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT vimazurov effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT asmisiyuk effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT ovsemagina effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT aesizikov effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy AT vnsorotskaya effectoftofacitinibonfunctionandqualityoflifeindicatorsinpatientswithrheumatoidarthritisresistanttosyntheticandbiologicaldiseasemodifyingantirheumaticdrugsinrealclinicalpracticeresultsofamulticenterobservationalstudy |
_version_ |
1721250291669532672 |